Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
9.12.2020 12:00:00 EET | Business Wire | Press release
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.
“The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.”
Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegen’s site.
Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheim’s Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheim’s Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.
“Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim,” said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. “Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.”
The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005383/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Makes Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra Available on Real Device Cloud Ahead of Retail Launch5.8.2026 15:30:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, announced that the Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra are now available for testing on its Real Device Cloud. Both devices, unveiled at Samsung's Galaxy Unpacked event, run Android 17 with One UI 9 and are accessible for live testing and automation before retail units reach customers. The launch generation introduces a testing challenge new to the Galaxy Z Fold line. The Galaxy Z Fold8 unfolds into a portrait-oriented 7.6-inch display, while the Galaxy Z Fold8 Ultra, the first Ultra model in the Z series, unfolds into a landscape-oriented 8.0-inch display. Two devices that share a name, a chipset, and an operating system present layouts with opposite orientations, which means an interface validated on one can break on the other. "Samsung has introduced two foldables with opposite unfolded orientations in the same generation, and that kind of form-factor diversity is exact
Riskified and Marqeta Partner to Sharpen Card Issuer Authorization Decisions and Help Reduce False Declines5.8.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced a partnership with Marqeta (NASDAQ: MQ), the global modern card issuing platform, to give card issuers on Marqeta's platform access to Riskified's pre-authorization risk intelligence. The integration helps issuers make more accurate authorization decisions, approve more legitimate transactions, and reduce false declines across Marqeta's issuing portfolio. False declines remain one of ecommerce's most costly and least visible problems. According to 2023 research by PYMNTS Intelligence and Nuvei, false declines put an estimated $157 billion in U.S. ecommerce sales at risk, with $81 billion ultimately lost even after consumers attempted to complete their purchases through subsequent payment attempts. Because issuers typically make authorization decisions with limited visibility into the broader merchant-consumer relationship, they too often decline legitimate orders alongside genuinely fraudu
NTT DATA AI for Insurance Converts Complex Workflows into Governed, Repeatable AI-delivered Services5.8.2026 15:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced NTT DATA AI for Insurance, an AI-native agentic solution that converts complex core insurance workflows into governed, repeatable services. Built for highly regulated insurance environments, the Service-as-Software solution combines configurable AI agents, insurance-specific data models, workflow orchestration and enterprise-grade governance to maintain auditability, regulatory guardrails and human oversight. NTT DATA AI for Insurance helps carriers modernize underwriting, claims, customer service and other core insurance workflows while improving productivity across the enterprise. Powered by NTT DATA AIVista, the company's AI-native product platform, the solution combines a prebuilt insurance foundation with flexible configuration and targeted customization, enabling rapid deployment while adapting to each carrier's products, processes, operating model and regulatory requirements. The solution
‘Cheers to Beer’ Celebrates the Drink at the Heart of Life’s Meaningful Moments5.8.2026 15:00:00 EEST | Press release
Ahead of International Beer Day on August 7th, AB InBev, the world's leading brewer, launched “Cheers to Beer,” a new global campaign celebrating the timeless role beer plays in culture and communities around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805206698/en/ The campaign is anchored by a new film, created in partnership with Wieden+Kennedy, that celebrates the many moments of cheers that beer creates across geographies and generations. The film, which will be amplified globally, reinforces beer's role in life’s meaningful moments, big and small. “Beer is universal and woven into cultures and communities around the world,” said Michel Doukeris, CEO, AB InBev. “No matter who you are, what you do for a living, or where you live, when someone says, ‘Let’s grab a beer,’ you know it means something more. It’s an invitation to celebrate or to simply connect.” Beer’s enduring relevance is reinforced by a new
Tecnotree saavutti kaksinumeroisen tuloskasvun ja vauhditti toimituksia vuoden 2026 ensimmäisellä puoliskolla5.8.2026 14:04:00 EEST | Tiedote
Tecnotree, maailmanlaajuinen tekoälynatiivien digitaalisten liiketoiminnan tukijärjestelmien (BSS) ja televiestintäalan digitaalisten alustaratkaisujen toimittaja, julkisti vuoden 2026 ensimmäisen vuosipuoliskon taloudellisen tuloksensa. Yhtiö saavutti kasvua kaikissa keskeisissä taloudellisissa tunnusluvuissaan, paransi liikevoittomarginaaliaan 800 peruspisteellä ja eteni ennätyksellisen tilauskantansa toimittamisessa ripeästi. Pohjois-Amerikassa, Afrikassa ja Lähi-idässä toteutettiin yhteensä kahdeksan tuotantoonvientiä. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20260805483151/fi/ Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 2026 Ensimmäinen vuosipuolisko (tammi–kesäkuu 2026) Liikevaihto oli 36,8 miljoonaa euroa (34,2 miljoonaa euroa), mikä merkitsee 7,5 prosentin kasvua edellisvuodesta. Vertailukelpoisin valuuttakurssein liikevaihto oli 37,6 miljoonaa euroa, jossa kasvua ol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom